hyaluronidase
Showing 1 - 25 of 273
Microstomia, Scleroderma Trial (Hyaluronidase, co2 laser)
Not yet recruiting
- Microstomia
- Scleroderma
- Hyaluronidase
- co2 laser
- (no location specified)
Aug 16, 2023
NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Pembrolizumab co-formulated with hyaluronidase
- Pembrolizumab
- (no location specified)
Oct 19, 2023
Pain, Postoperative Trial in Banha (Hyaluronidase, Bupivacaine Injection)
Recruiting
- Pain, Postoperative
- Hyaluronidase
- Bupivacaine Injection
-
Banhā, Qalubia, EgyptSamar Rafik Amin
Jan 1, 2023
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Scottsdale, Jacksonville, Rochester
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8
- Biopsy
- +7 more
-
Scottsdale, Arizona
- +2 more
Feb 15, 2023
Health, Subjective Trial in Seoul (BMI2004, 0.9% NaCl)
Completed
- Health, Subjective
- BMI2004
- 0.9% NaCl
-
Seoul, Heukseok-ro, Dongjak-gu, Korea, Republic ofChung-Ang University Hospital
Jun 26, 2023
T-cell Acute Lymphoblastic Leukemia Trial in Chicago (Daratumumab / Hyaluronidase Injection)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Daratumumab / Hyaluronidase Injection
-
Chicago, IllinoisNorthwestern
Jun 17, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Edema, Pain, Trismus Trial in Nicosia, Ankara (Hyaluronidase Injection mesomedica, Dexamethasone dekort)
Completed
- Edema
- +3 more
- Hyaluronidase Injection mesomedica
- Dexamethasone dekort
-
Nicosia, Cyprus
- +1 more
Jul 15, 2022
Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)
Not yet recruiting
- Metastatic Non-small Cell Lung Cancer
- Pembrolizumab coformulated with hyaluronidase
- +6 more
- (no location specified)
Jan 27, 2023
HIV Trial in Las Vegas (Cabotegravir 200 mg/mL, Cabotegravir 400 mg/mL, Recombinant human hyaluronidase PH20 (rHuPH20))
Recruiting
- HIV Infections
- Cabotegravir 200 mg/mL
- +2 more
-
Orlando, Florida
- +3 more
Dec 1, 2022
Multiple Myeloma Trial in United States (TTI-622, Daratumumab Hyaluronidase-fihj)
Recruiting
- Multiple Myeloma
- TTI-622
- Daratumumab Hyaluronidase-fihj
-
Basking Ridge, New Jersey
- +6 more
Dec 8, 2022
Plasma Cell Myeloma Trial in Philadelphia (Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life
Not yet recruiting
- Plasma Cell Myeloma
- Daratumumab and Hyaluronidase-fihj
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Aug 19, 2022
Drug Safety Trial in Chicago (Hyaluronidase)
Active, not recruiting
- Drug Safety
- Hyaluronidase
-
Chicago, IllinoisNorthwestern University Department of Dermatology
Jan 4, 2022
Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- HYQVIA
- (no location specified)
Feb 23, 2023
Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- +2 more
-
Washington, District of Columbia
- +1 more
Mar 14, 2022
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,
Recruiting
- Burkitt Lymphoma
- +2 more
- Rituximab and Hyaluronidase Human
- +8 more
-
Kampala, UgandaUCI-Fred Hutch Cancer Centre
Mar 9, 2022
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance Trial in Washington (Daratumumab and
Not yet recruiting
- Peripheral Neuropathy
- Monoclonal Gammopathy of Undetermined Significance
- Daratumumab and hyaluronidase-fihj
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Sep 14, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC
Active, not recruiting
- Multiple Myeloma
- Daratumumab Subcutaneous (SC) Administration
- Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
-
Atlanta, Georgia
- +11 more
Aug 11, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8 Trial in Los Angeles (Atezolizumab
Recruiting
- Lung Non-Small Cell Carcinoma
- +10 more
- Atezolizumab and Recombinant Human Hyaluronidase
- Survey Administration
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Jan 31, 2023
Muscle Spasticity Trial in Baltimore (Hyaluronidase, Placebo)
Recruiting
- Muscle Spasticity
- Hyaluronidase
- Placebo
-
Baltimore, MarylandParia Arfa Fatollahkhani, MD, M.Sc.
Oct 28, 2022
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
Postoperative Pain Trial in Sohag (Hyaluronidase)
Recruiting
- Postoperative Pain
- Hyaluronidase
-
Sohag, EgyptSohag University Hospital
Oct 19, 2021
HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)
Completed
- HIV Antibodies
- VRC-HIVMAB091-00-AB
- EDP
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 8, 2022